Bicycle Therapeutics Plc ADR (BCYC) Shares Up Despite Recent Market Volatility

Bicycle Therapeutics Plc ADR (NASDAQ: BCYC)’s stock price has gone rise by 18.21 in comparison to its previous close of 21.42, however, the company has experienced a 14.16% increase in its stock price over the last five trading days. businesswire.com reported 2024-05-23 that CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25,933,706 American Depositary Shares (“ADSs”), each representing one ordinary share, and in lieu.

Is It Worth Investing in Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Right Now?

Moreover, the 36-month beta value for BCYC is 0.86. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for BCYC is 42.13M and currently, short sellers hold a 6.62% of that float. On May 23, 2024, BCYC’s average trading volume was 356.84K shares.

BCYC’s Market Performance

BCYC stock saw an increase of 14.16% in the past week, with a monthly gain of 11.69% and a quarterly increase of 2.76%. The volatility ratio for the week is 4.28%, and the volatility levels for the last 30 days are 5.14% for Bicycle Therapeutics Plc ADR (BCYC). The simple moving average for the last 20 days is 10.79% for BCYC’s stock, with a simple moving average of 25.58% for the last 200 days.

Analysts’ Opinion of BCYC

Barclays gave a rating of “Overweight” to BCYC, setting the target price at $30 in the report published on July 28th of the previous year.

BCYC Trading at 8.55% from the 50-Day Moving Average

After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.42% of loss for the given period.

Volatility was left at 5.14%, however, over the last 30 days, the volatility rate increased by 4.28%, as shares surge +13.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.23% lower at present.

During the last 5 trading sessions, BCYC rose by +14.92%, which changed the moving average for the period of 200-days by +13.29% in comparison to the 20-day moving average, which settled at $23.00. In addition, Bicycle Therapeutics Plc ADR saw 40.04% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BCYC starting from Hannay Michael Charles Ferguso, who sale 257 shares at the price of $22.49 back on Apr 11 ’24. After this action, Hannay Michael Charles Ferguso now owns 22,891 shares of Bicycle Therapeutics Plc ADR, valued at $5,780 using the latest closing price.

Lee Kevin, the CHIEF EXECUTIVE OFFICER of Bicycle Therapeutics Plc ADR, sale 3,158 shares at $23.81 during a trade that took place back on Apr 03 ’24, which means that Lee Kevin is holding 387,270 shares at $75,192 based on the most recent closing price.

Stock Fundamentals for BCYC

Current profitability levels for the company are sitting at:

  • -4.7 for the present operating margin
  • 0.84 for the gross margin

The net margin for Bicycle Therapeutics Plc ADR stands at -4.04. The total capital return value is set at -0.39. Equity return is now at value -56.21, with -34.51 for asset returns.

Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -2.38. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -59.7.

Currently, EBITDA for the company is -168.8 million with net debt to EBITDA at 2.32. When we switch over and look at the enterprise to sales, we see a ratio of 16.02. The receivables turnover for the company is 1.06for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.42.

Conclusion

To wrap up, the performance of Bicycle Therapeutics Plc ADR (BCYC) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts